Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 6/20 | 0.59 |
| ▸ | FYN | P06241 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 5/20 | 0.53 |
| ▸ | DRD2 | P14416 | 5/20 | 0.53 |
| ▸ | DRD4 | P21917 | 3/20 | 0.53 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | DRD5 | P21918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8765625 | 1.00 | GRIN2B (0.59) | GRIN2BFYNDRD3DRD2DRD4 | |
| Hydrochloric Acid SCHEMBL5144064 | 0.99 | GRIN2B (0.58) | GRIN2BFYNDRD3DRD2DRD4 | |
| Hydrochloric Acid SCHEMBL8765161 | 0.99 | GRIN2B (0.58) | GRIN2BFYNDRD3DRD2DRD4 | |
| SCHEMBL8765804 | 0.96 | GRIN2B (0.58) | GRIN2BFYNDRD3DRD2DRD4 | |
| SCHEMBL5146440 | 0.95 | GRIN2B (0.59) | GRIN2BFYNDRD3DRD2DRD4 | |
| SCHEMBL9304253 | 0.92 | GRIN2B (0.71) | GRIN2BFYNDRD3DRD2DRD4 | |
| SCHEMBL9306071 | 0.92 | GRIN2B (0.71) | GRIN2BFYNDRD3DRD2DRD4 | |
| SCHEMBL6133948 | 0.92 | GRIN2B (0.71) | GRIN2BFYNDRD3DRD2DRD4 | |
| Bromide SCHEMBL9304413 | 0.91 | GRIN2B (0.69) | GRIN2BFYNDRD3DRD2DRD4 | |
| Bromide SCHEMBL9303647 | 0.91 | GRIN2B (0.69) | GRIN2BFYNDRD3DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217706-B2 | Propanolamine derivatives | ASTELLAS PHARMA INC. (JP) | 2007-05-15 | — | — | US | disclosed |
| EP-1382333-A2 | Use of beta 3 adrenergic receptor agonists in the treatment of dysuria | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-21 | — | — | EP | disclosed |
| US-6495546-B1 | SUCH AS 1-(N-BENZYL-N-(3-METHOXY-6,7,8,9-TETRAHYDRO-5H-BENZO-CYCLOHEPTEN-6-YL)AMINO)-3-PHENOXY-2-PROPANOL; ADRENERGIC RECEPTOR AGONISTS; ANTIULCEROUS, LIPOLYTIC, ANTIURINARY INCONTINENCE AND ANTIPOLLAKIURIA ACTIVITIES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| US-20020120148-A1 | Propanolamine derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-08-29 | — | — | US | disclosed |
| EP-1070046-A1 | PROPANOLAMINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999051564-A1 | PROPANOLAMINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-14 | — | — | WO | disclosed |
| EP-0583485-B1 | ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-08-13 | — | — | EP | disclosed |
| US-5387710-A | Ethanolamine derivatives having sympathomimetic and anti-pollakiuria activities | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-07 | — | — | US | disclosed |
| EP-0583485-A1 | ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES. | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-02-23 | — | — | EP | disclosed |
| WO-1993015041-A1 | ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120148-A1 | Propanolamine derivatives | AMY2A, PNMT, PNLIP | GRIN2B 4555/4885FYN 4753/4885DRD3 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.